ALISO VIEJO, Calif., Oct. 8, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will host an Investor Relations Briefing on Wednesday, October 15, 2014 at 7:30 a.m. ET in New York City. At the meeting, members of the Avanir senior management team will provide a company update and discuss the results from the phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.
To view and listen to the webcast please visit our website at http://ir.avanir.com. Visitors will also be able to view and listen to an archive copy of the webcast found in the Investor Relations section of www.avanir.com. The archive will be available for 30 days following the event.
For more information on the Investor Relations Briefing please refer to contact information within this press release.
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.
AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.
©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.
Avanir Investor & Media Contact
Ian Clements, PhD
+1 (949) 389-6700
Burns McClellan Contact
+1 (212) 213-0006
Logo - http://photos.prnewswire.com/prnh/20130207/LA55901LOGO
SOURCE Avanir Pharmaceuticals, Inc.